Why the weight, and heart risks, return after stopping GLP-1 drugs

Elizabeth Cooney, a cardiovascular disease reporter at STAT, recently covered the impact of weight loss drugs on various health conditions. The benefits of these medications extend beyond just weight loss, offering relief for type 2 diabetes, heart failure, and clogged arteries that can lead to serious cardiovascular events like heart attacks and stroke. Additionally, obesity medications have shown promise in helping individuals with sleep apnea and addiction.

However, despite the numerous health benefits, the use of weight loss drugs comes with challenges. One major issue is the high cost associated with these medications, as well as troubling side effects that some individuals may experience. Another significant drawback is the high rate of discontinuation among users – roughly half of individuals who start on weight loss drugs stop taking them within a year, with the rate climbing to 60% among older individuals with diabetes.

A recent systematic review published in the BMJ highlights another concerning finding related to the discontinuation of GLP-1s, a class of obesity medications. The study revealed that when individuals stop taking these drugs, not only do they regain the weight they lost, but they also experience a reversal of key markers associated with heart disease risk. This reversal is more pronounced compared to individuals who discontinue behavioral weight management programs that do not involve drug therapy.

The findings underscore the importance of adherence to weight loss medications for long-term health benefits. Despite the challenges and potential drawbacks, these medications play a crucial role in managing obesity and its associated health conditions. It is essential for healthcare providers to work closely with patients to address concerns, manage side effects, and provide ongoing support to promote medication adherence and achieve optimal health outcomes.